Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).
1 finding from 1 review
Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma
Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Resolution of encephalopathy and coagulopathy · children with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · children with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Liver Transplant · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in liver transplant compared with placebo (low certainty).
1 finding from 1 review
Resolution of encephalopathy and coagulopathy · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adult patients with non‐paracetamol (acetaminophen)‐related acute liver failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Liver Transplant · children with non‐paracetamol (acetaminophen)‐related acute liver failure
N‐acetylcysteine showed no clear difference in liver Transplant compared with placebo (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sorafenib showed no clear difference in progression‐free survival (absolute effect size estimates based on… compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review